Latest Articles

Publication Date
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace

Published: Feb. 4, 2026, 4:47 a.m.
Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer TradingView

Published: Feb. 3, 2026, 1:11 p.m.
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Newswire Canada

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Newswire …

Published: Feb. 3, 2026, 1 p.m.
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Yahoo Finance Singapore

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Yahoo …

Published: Feb. 3, 2026, 1 p.m.
Emerging Trends and Treatment Strategies in Ovarian Cancer: A Comprehensive Review.

Ovarian cancer (OC) is the eighth leading cause of cancer deaths in women globally, mainly originating from epithelial cells. It is further divided into type-I and type-II based on histology, …

Published: Feb. 3, 2026, midnight
HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma.

Ovarian clear cell carcinoma (CCC) is an aggressive subtype of ovarian cancer that is resistant to conventional chemotherapy, resulting in poor prognosis. CCC develops from endometriosis, which exposes tumor cells …

Published: Jan. 27, 2026, midnight
Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery - Cureus

Management of Suspected Stage IVA Endometrial Cancer With Rectosigmoid Involvement Using Neoadjuvant Chemotherapy and Interval Surgery Cureus

Published: Jan. 21, 2026, 1:51 p.m.
[Laparoscopic Resection of an Ectopic Endometriosis-Associated Carcinoma Arising in the Rectum-A Case Report].

A woman in her seventies presented with mucous hematochezia. Colonoscopy revealed a poorly differentiated adenocarcinoma in the upper rectum. Immunohistochemical staining showed CK7 positivity and CK20/CDX2 negativity, findings atypical for …

Published: Jan. 18, 2026, midnight
Collision tumor of endometrial hepatoid adenocarcinoma and endometrial stromal sarcoma: a rare case and literature review.

Endometrial hepatoid adenocarcinoma (HAC) is an exceedingly rare tumor. Histologically, the tumor is predominantly characterized by HAC with additional components, as documented in previous reports. The coexistence of endometrial HAC …

Published: Jan. 16, 2026, midnight
Therapeutic potential of epigallocatechin gallate in gynecologic cancer, endometriosis, polycystic ovary syndrome: a mechanistic and translational perspective.

Tea, among the most widely consumed beverages worldwide, is rich in polyphenolic compounds known as catechins, particularly epigallocatechin gallate (EGCG). This review aims to synthesize recent findings and ongoing controversies …

Published: Jan. 13, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!